Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

The role of noradrenergic innervation and β-cell dedifferentiation in diabetes

Noradrenergic innervation and β-cell dedifferentiation in diabetes.

Dedifferentiation, a survival mechanism whereby mature β-cells revert to a nonfunctional state under metabolic stress, represents a fundamental driver of β-cell failure in type 2 diabetes.

Dedifferentiation is reversible, primarily through dietary intervention or bariatric surgery, and redifferentiation may promote type 2 diabetes remission.

Noradrenergic fiber density is increased in diabetic pancreases and correlates with β-cell dedifferentiation, suggesting that altered signaling may trigger the process.

A link between diet, redifferentiation, reduction of noradrenergic fibers, and type 2 diabetes remission has been hypothesized.

The review proposes that targeting pancreatic noradrenergic innervation could be a novel therapeutic strategy to reverse β-cell dedifferentiation, restore insulin function, and achieve type 2 diabetes remission. sciencenewshighlights ScienceMission https://sciencemission.com/noradrenergic-innervation–in-diabetes

Continue reading “The role of noradrenergic innervation and β-cell dedifferentiation in diabetes” | >

Baicalein Alleviates Iron Overload-Induced Ferroptosis and Osteogenic Blockade in Osteoblasts by Activating the Nrf2/GPX4 Pathway

JUST PUBLISHED:Click here to read the latest free, Open Access article from BMEF.

The transcription factor Nrf2 orchestrates cellular defenses against redox imbalance and lipid peroxidation, partly through regulating the expression of 2 key gatekeepers of ferroptosis: SLC7A11 and GPX4 [44]. As such, the Keap1/Nrf2 pathway is recognized as a master regulator of ferroptosis in osteoblasts [45]. Under stress conditions, Nrf2 dissociates from the Keap1–Nrf2 complex, translocates into the nucleus, and initiates the transcription of genes containing antioxidant response elements [46]. Previous studies have reported that Nrf2 activation protects osteoblasts from ferroptosis in bone tissue and alleviates osteoporosis [28,47]. Consistently, we observed that under iron overload conditions, baicalein restored nuclear Nrf2 levels and the expression of downstream targets GPX4 and SLC7A11. Both genetic and pharmacological inhibition of Nrf2 abolished the cytoprotective and pro-osteogenic effects of baicalein. These findings suggest that baicalein prevents ferroptosis in osteoblasts via activation of the Nrf2/GPX4 pathway.

Clinically, iron overload conditions, such as transfusion-induced iron overload in thalassemia and hereditary hemochromatosis, are strongly associated with low bone mass and increased fracture risk [48,49]. Current treatment options (e.g., iron chelators, phlebotomy, and anti-resorptive agents) fail to simultaneously address iron overload and bone damage. Baicalein has undergone human safety and pharmacokinetic studies, which indicate no significant side effects even at high doses [50,51]. Our study demonstrates that baicalein not only prevents bone loss by protecting osteoblasts from ferroptosis but also effectively reduces systemic iron storage. Although beyond the scope of this work, baicalein’s known anti-osteoclastogenic effects may synergistically contribute to its overall bone-protective actions in iron overload conditions. These findings suggest that baicalein is a promising therapeutic agent for iron overload-related bone disorders. Although clinical trials are warranted, the dose of baicalein used in our study was extrapolated from clinically tolerated doses in humans, thereby supporting the potential feasibility of its clinical application.

In summary, this study provides the first definitive evidence that baicalein effectively inhibits iron overload-induced ferroptosis in osteoblasts by activating the Nrf2/GPX4 signaling pathway, thereby promoting bone formation and preventing bone loss. Our findings not only elucidate the mechanism by which baicalein functions as a novel ferroptosis inhibitor in bone protection but also highlight its role as a “dual-function” therapeutic strategy—combining iron chelation and anti-bone-loss capacities. Given its favorable safety profile and existing human pharmacokinetic data, our results provide strong preclinical evidence supporting the clinical translation of baicalein for the treatment of iron overload-related bone diseases. Targeting the ferroptosis pathway, particularly via Nrf2/GPX4 activation by baicalein, represents a highly promising novel strategy for preventing and treating iron overload-induced bone loss.

The first personalized brain repair for Parkinson’s

Parkinson’s disease has been a repetitive pattern of tremors, stiffness, slowing movement and an eventual dependence on medications that soften (but never stop) the decline. But what if that script is no longer fixed? What if the brain, instead of being carefully managed as it deteriorates, could actually be rebuilt from the patient’s own biology?

These questions are no longer purely theoretical. In early clinical data presented at the AD/PD 2026 International Conference in Copenhagen, San Diego-based biotech Aspen Neuroscience shared results suggesting an unusual finding in neurodegenerative disease: early signs of restoration [1]. Not slowing, not masking, but restoring.

At the center of Aspen’s approach is a radical idea of using the patient’s own cells as raw material to rebuild what Parkinson’s has taken away.

Brain-based index may reveal Alzheimer’s risk patterns in adults as young as 30

Over the past few decades, neuroscientists and medical researchers worldwide have been trying to leverage available health records, brain scans and other medical data to uncover biological markers associated with the onset of specific diseases or neuropsychiatric disorders. The identification of these biomarkers could help to devise new tools to predict the risk that individual patients will develop a specific condition, allowing doctors to intervene early, preventing or delaying its emergence or slowing down its progression.

Researchers at the University of Texas Health Science Center, UTHealth Houston School of Behavioral Health Sciences, Keck School of Medicine of USC, and University of Maryland School of Medicine recently devised a new brain-based index that could be used to track early risk factors that, in specific people, may lead to the development of Alzheimer’s disease (AD). AD is a progressive neurodegenerative condition that prompts the deterioration and death of brain cells, leading to progressive memory loss and a decline in mental functions. AD has very limited treatment options after the diagnosis but the brain changes that culminate in AD take decades, thus suggesting that public effort should be focused on prevention.

The researchers devised an index that could be used to quantify patterns in a person’s brain that measure the similarity to those observed in individuals diagnosed with AD and followed as a part of the research studies such as Alzheimer’s Disease Neuroimaging Initiative (ADNI). This index, introduced in a paper published in Molecular Psychiatry, was derived by performing a mega-analysis of publicly available brain imaging data collected from people with and without AD.

Durable ionogel withstands 5,000 times its weight while staying soft on skin

The development of soft materials that can reliably function on the human body is important for the future of bioelectronics and wearable medical devices. These materials need to comfortably conform to the skin while being durable enough for everyday use. However, many existing soft materials are easily damaged, limiting their practical applications.

A research team led by Professor Lizhi Xu from the Department of Mechanical Engineering under the Faculty of Engineering at the University of Hong Kong (HKU) has created a new type of ionogel that overcomes this challenge. The material is soft and flexible, yet strong enough to withstand significant mechanical stress, making it ideal for wearable and biomedical applications.

The research is published in the journal Science Advances, in an article titled “High-strength and fracture-resistant ionogels via solvent-tailored interphase cohesion in nanofibrous composite networks.”

Chemistry-aware AI can generate millions of plausible new molecules

Finding and developing new molecules is one of the great research endeavors of modern chemistry. From the development of new drugs to the creation of more sustainable materials, everything depends on finding new combinations of atoms with useful properties. Now, a research team from the Universitat Rovira i Virgili (URV) has developed an artificial intelligence tool capable of generating millions of new molecules which, although still unknown to science, comply with the laws of chemistry and could therefore be realistic possibilities. The research results have been published in the journal Nature Machine Intelligence.

The system, called CoCoGraph, works in a similar way to generative artificial intelligence tools for text or images, such as ChatGPT or Dall-E. “These models create new content that looks very much like the real thing. Our algorithm does the same, but with molecules,” explains Roger Guimerà, an ICREA Research Professor in the Department of Chemical Engineering at the URV.

Unlike other AI tools, however, the model does not yet respond to specific instructions. For the moment it simply carries out the more basic task of generating plausible molecules, that is, structures that comply with the rules of chemistry.

Why isolated human groups speak more diverse languages even as genetic diversity shrinks

Languages and human DNA both capture aspects of human diversity. But how are they related? A new international study led by the University of Zurich finds a clear but counterintuitive pattern: regions with high genetic diversity tend to have more similar languages, while isolated populations with low genetic diversity show greater linguistic diversity. The research is published in the journal Proceedings of the National Academy of Sciences.

At first glance, the findings seem surprising. One might expect regions with greater genetic diversity, often shaped by migration and population mixing, to also show greater diversity in language. But the study reveals the opposite.

“We were struck by how robust this inverse relationship is across the globe,” says Anna Graff, lead author of the study and linguist at the University of Zurich. “Places where people have mixed more tend to be genetically diverse, but their languages are structurally more similar. In contrast, places with long-term isolation show less genetic diversity, yet much greater diversity in how languages are structured. Crucially, this relationship holds after adjusting for a wide range of confounding factors, including deep population history such as the timing of continental settlement.”

Epigenetic Skin Aging and Its Reversal to Improve Skin Longevity across Ethnicities and Phototypes Using a Dihydromyricetin-Containing Serum: Results from a Prospective, Single-Cohort Study — Dermatology and Therapy

Skin aging is driven by intrinsic and extrinsic factors. Epigenetic alterations are one primary hallmark of aging and powerful biomarkers of biological skin age. To investigate epigenetic skin aging mechanisms and their regulation as a skin longevity approach across diverse ethnicities and phototypes, we assessed epidermal methylomes from white, African, and Asian donors.

We collected epidermis samples from 17 multi-ethnic donors with diverse phototypes using a newly established tape-stripping method followed by array-based DNA methylation profiling to investigate the robustness of DNA methylation clocks across diverse ethnic backgrounds. Additionally, we conducted a clinical study with 60 participants representing Fitzpatrick phototypes I–VI. Diverse clinical parameters and biological skin age of the volunteers were determined at baseline and after applying a serum containing the natural epigenetic inhibitor dihydromyricetin (DHM) for 8 weeks to investigate skin longevity effects across phototypes.

Data analysis revealed that age-dependent DNA hypermethylation is conserved across populations and affects genes essential for keratinocyte vitality and longevity. A newly developed epidermal methylation clock accurately predicted biological age in multi-ethnic cohorts, confirming the robustness of epigenetic age estimation across phototypes. Topical application of a DHM-containing serum significantly reduced epidermal DNA methylation age. Epigenetic rejuvenation was associated with clinical improvements, including reduced skin roughness and wrinkle visibility and occupancy, and increased dermal echogenicity.

New DNA-Based Therapy Can Help Lower ‘Bad Cholesterol’ Without Statins, Finds Study

Scientists may have found a powerful new way to lower “bad” cholesterol, which did not involve the use of statin medicines. In a recent study, researchers used tiny DNA-based molecules to cut levels of LDL (bad) cholesterol by nearly 50% in animal models. This was done without the side effects that are often linked to statins. If these results stay consistent in large human trials, the therapy could become an important option for people who cannot tolerate statins or who still have high cholesterol despite taking them. The study was led by Carles J. Ciudad and Veronica Noe from the University of Barcelona’s Faculty of Pharmacy and Food Sciences and the Institute of Nanoscience and Nanotechnology (IN2UB), working with Nathalie Pamir at the University of Oregon in Portland (United States). It was published in the journal Biochemical Pharmacology.

High LDL cholesterol is one of the biggest risk factors for heart attacks and strokes because it leads to the build up fatty plaques in arteries. Drugs like statins work well for many, but some people suffer from muscle aches, digestive issues, or liver problems and have to stop them. However, the new approach is different. Instead of changing how the liver handles fats, it targets a specific protein in the blood that controls how much LDL stays circulating.

/* */